Voyager Therapeutics, Inc. (VYGR)
3.42
-0.03
(-0.87%)
USD |
NASDAQ |
Sep 01, 16:00
3.42
0.00 (0.00%)
After-Hours: 20:00
Voyager Therapeutics Enterprise Value : 127.62M for Aug. 31, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 31, 2026 | 127.62M |
| August 28, 2026 | 133.14M |
| August 27, 2026 | 128.24M |
| August 26, 2026 | 128.24M |
| August 25, 2026 | 129.46M |
| August 24, 2026 | 127.01M |
| August 21, 2026 | 123.95M |
| August 20, 2026 | 119.66M |
| August 19, 2026 | 125.17M |
| August 18, 2026 | 118.43M |
| August 17, 2026 | 114.14M |
| August 14, 2026 | 116.59M |
| August 13, 2026 | 113.53M |
| August 12, 2026 | 112.30M |
| August 11, 2026 | 112.30M |
| August 10, 2026 | 110.47M |
| August 07, 2026 | 116.59M |
| August 06, 2026 | 108.01M |
| August 05, 2026 | 106.18M |
| August 04, 2026 | 107.71M |
| August 03, 2026 | 100.05M |
| July 31, 2026 | 101.89M |
| July 30, 2026 | 108.01M |
| July 29, 2026 | 100.05M |
| July 28, 2026 | 102.50M |
| Date | Value |
|---|---|
| July 27, 2026 | 105.56M |
| July 24, 2026 | 106.18M |
| July 23, 2026 | 105.56M |
| July 22, 2026 | 106.18M |
| July 21, 2026 | 108.63M |
| July 20, 2026 | 103.11M |
| July 17, 2026 | 110.47M |
| July 16, 2026 | 102.50M |
| July 15, 2026 | 112.30M |
| July 14, 2026 | 109.85M |
| July 13, 2026 | 114.75M |
| July 10, 2026 | 127.01M |
| July 09, 2026 | 141.72M |
| July 08, 2026 | 144.78M |
| July 07, 2026 | 147.84M |
| July 06, 2026 | 138.04M |
| July 02, 2026 | 147.84M |
| July 01, 2026 | 136.81M |
| June 30, 2026 | 130.69M |
| June 29, 2026 | 109.00M |
| June 26, 2026 | 109.60M |
| June 25, 2026 | 107.19M |
| June 24, 2026 | 115.03M |
| June 23, 2026 | 116.24M |
| June 22, 2026 | 117.44M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 588.96M |
| Amgen, Inc. | 275.71B |
| Anika Therapeutics, Inc. | 266.14M |
| BioCryst Pharmaceuticals, Inc. | 2.960B |
| Imunon, Inc. | 8.586M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -24.47M |
| Revenue (Quarterly) | 3.165M |
| Total Expenses (Quarterly) | 27.64M |
| EPS Diluted (Quarterly) | -0.4042 |
| Gross Profit Margin (Quarterly) | 71.31% |
| Profit Margin (Quarterly) | -773.2% |
| Earnings Yield | -53.02% |
| Normalized Earnings Yield | -53.02 |